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SUMMARY
Due to the growing number of liver transplantations (LTs), there is an
increasing number of patients requiring retransplantation (reLT). Data on
the use of grafts from extended criteria donors (ECD), especially donation
after circulatory death (DCD), for reLT are lacking. We aimed to assess
the outcome of patients undergoing reLT using a DCD graft in the Nether-
lands between 2001 and July 2018. Propensity score matching was used to
match each DCD‐reLT with three DBD‐reLT cases. Primary outcomes were
patient and graft survival. Secondary outcome was the incidence of biliary
complications, especially nonanastomotic strictures (NAS). 21 DCD‐reLT
were compared with 63 matched DBD‐reLTs. Donors in the DCD‐reLT
group had a significantly lower BMI (22.4 vs. 24.7 kg/m2, P‐value = 0.02).
Comparison of recipient demographics and ischemia times yielded no sig-
nificant differences. Patient and graft survival rates were comparable
between the two groups. However, the occurrence of nonanastomotic stric-
tures after DCD‐reLT was significantly higher (38.1% vs. 12.7%, P‐
value = 0.02). ReLT with DCD grafts does not result in inferior patient
and graft survival compared with DBD grafts in selected patients. There-
fore, DCD liver grafts should not routinely be declined for patients await-
ing reLT.
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Introduction
Liver transplantation (LT) is a well‐established treat-
ment for patients suffering from end‐stage liver disease.
Due to the scarcity of available organs from deceased
donors, the use of grafts from extended criteria donors
(ECD) has increased substantially, of which grafts from
donation after circulatory death (DCD) is a main
parameter (1). In 2018, a DCD graft was used in 38%
and 9% of all deceased donor LT in the Netherlands
and United States of America, respectively (2,3). In the
United Kingdom, 26% of deceased donor LT were per-
formed with DCD grafts (4).
Liver transplantation with DCD grafts (DCD‐LT) is
considered to be inferior compared to LT with grafts
donated after brain death (DBD‐LT), due to the
increased risk of complications such as early allograft
dysfunction (EAD) and biliary complications (5–8).
Among biliary complications, nonanastomotic strictures
(NAS) are the most feared as they often require multi-
ple interventions for biliary drainage, are largely irre-
versible and are known to have a negative impact on
recipient and graft survival (9). The incidence of NAS,
also known as ischemic cholangiopathy (IC) or
ischemic‐type biliary lesions (ITBL), after DCD‐LT var-
ies between 3% and 39% (6).
Since the use of grafts from marginal donors has
increased, it is assumed that more recipients will develop
post‐transplant complications related to a suboptimal
graft. Furthermore, due to improvements in surgical
techniques, postoperative care and immunosuppressive
regimes, the short‐term survival after LT has improved
significantly (10), resulting in a larger population surviv-
ing long enough to develop late graft failure. A retrans-
plantation of the liver (reLT) is currently the only
definitive treatment for allograft failure. However, it is
well known that reLT is associated with inferior patient
and graft survival compared with primary LT (11,12).
Despite DCD liver grafts being widely accepted, trans-
plant physicians and surgeons tend to avoid the use of
DCD grafts for reLT. However, since in some countries
the availability of DBD grafts has decreased (13), the
waiting time for an optimal, preferably DBD liver to
become available for a reLT candidate could be too long
with subsequent risk of deterioration of patient’s condi-
tion, making him or her ineligible for reLT.
There is very little reported on the use of DCD grafts
for patients requiring a reLT. Only one study has
assessed the outcomes of ten patients undergoing reLT
using DCD grafts (14). The authors concluded that the
use of DCD graft should be avoided if the recipient has
a moderate to high Model for End‐Stage Liver Disease
(MELD) score. Unfortunately, no comparison was made
with reLT using DBD grafts. Since DCD‐LT is common
in the Netherlands, and reLT is not an official con-
traindication for the use of a DCD liver, we aimed to
compare the outcomes of reLT with DCD grafts in the
Netherlands with that of matched DBD cases.
Patients and methods
In this multicenter retrospective study, all patients who
underwent reLT using a controlled DCD liver graft
(DCD‐reLT) in the Netherlands from the beginning of
the DCD‐LT program in 2001 until July 1st 2018, were
included. Pediatric LT (recipient < 18 years), reLT using
a split graft, reLT in the setting of multi‐organ transplan-
tation and grafts preserved with machine perfusion were
excluded. A pre‐existent nationwide database on all liver
retransplantations (reLT) performed between 1979 and
July 2018 was used to match each DCD‐reLT to three
cases of reLT with DBD grafts (DBD‐reLT) (15). For the
matching, a propensity score matching approach with
nearest‐neighbor algorithm was used. The propensity
scores were calculated using a logistic regression model
with the following independent covariates: transplant
center, number of consecutive reLT, year of reLT, donor
and recipient age, last laboratory MELD score (Model of
End‐Stage Liver Disease) registered by Eurotransplant
prior to transplantation, cold ischemia time (CIT), and
interval between prior LT and ReLT. This latter matching
criterion was chosen since an early reLT, is on the one
hand technically less challenging than late reLT (easier
hepatectomy with less adhesions), but on the other hand
is performed in patients who may be sicker pre‐reLT than
patients undergoing a late reLT (16,17). DBD‐reLT cases
that met one of the previously mentioned exclusion crite-
ria or had missing variables in one or more of the match-
ing criteria were excluded prior to matching. Additional
data on donor and organ procurement characteristics
were obtained through the Eurotransplant Donor data
database. Additional recipient data and data on follow‐up
were collected from prospective maintained databases
and patients’ electronic medical records. The study has
been approved by the Institutional Review Board of the
Erasmus MC University Medical Center Rotterdam
(MEC‐2019‐0316).
In all DCD organ procurements in the Netherlands,
withdrawal of life support takes place at the ICU or reg-
ular ward. After circulatory arrest, a mandatory no
touch period of five minutes is carried out after which
the donor is transported to the operating theatre. As
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described in the National protocol postmortem donor
organ procurement, a super‐rapid retrieval technique is
used in DCD donors to minimize the donor warm
ischemia time (dWIT). After cannulation of aorta and
inferior vena cava, cold perfusion with University of
Wisconsin (UW) solution is started (18). Since pre-
mortem administration of heparin is prohibited by law,
heparin is added to the perfusion solution. The stan-
dard method of implantation is with a piggyback caval
vein anastomosis, an end‐to‐end arterial and portal
anastomosis, and a duct‐to‐duct biliary anastomosis.
The total dWIT was defined as time between with-
drawal of life‐supporting treatment and start of cold per-
fusion. The definition of asystolic dWIT was the time
between circulatory arrest and cold perfusion. The CIT
was defined as the period between the start of the cold
perfusion in the donor and the removal of the liver from
ice during the recipient procedure. The definition of
recipient warm ischemia time (rWIT) used in this study
is the interval between removal of the liver from ice and
graft reperfusion (i.e., in the majority portal reperfusion).
The primary outcome measures of this study were
patient and graft survival. Patient survival was defined
as time between reLT and death, with or without func-
tioning graft. Graft survival was calculated as time
between the reLT and patient death (with or without
functioning graft) or a successive retransplantation. Sec-
ondary outcomes were the incidence of three types of
biliary complications: bile leakage, anastomotic stric-
tures, and NAS. NAS was defined as any stricture of the
bile duct except those localized near the biliary anasto-
mosis and in absence of an hepatic artery thrombosis.
Continuous data were presented as median and
interquartile range (IQR) and compared with the Mann–
Whitney U test. Categorical variables were presented as
number and percentages and compared with the Pearson
chi‐square test or the Fisher exact test where appropriate.
Survival analyses was conducted using the Kaplan–Meier
method, and comparisons were made with the log‐rank
test. All tests were two‐sided with a P‐value below 0.05
considered as significant. The propensity score matching
was performed in RStudio, version 1.0.153 (RStudio Inc.
Boston, MA, USA), using the MatchIt package. All other
statistical analyses were performed using SPSS version 25
(IBM, Chicago, IL, USA).
Results
A total of 21 cases of DCD‐reLT were included in this
study. These cases were matched with 63 DBD‐reLT cases.
Donor and recipient demographics are given in Table 1.
Compared with DBD‐reLT donors, DCD‐reLT donors had
a significantly lower BMI (22.4 vs. 24.7 kg/m2, P‐
value = 0.02). Furthermore, there was a trend toward sig-
nificance regarding the donor cause of death (P‐
value = 0.06). The majority of the DBD donors had died
from a cerebrovascular accident (CVA), whereas the cause
of death among DCD donors was more equally distributed
between trauma, CVA, and other causes. In DCD‐reLT,
the median asystolic dWIT was 15.0 min (12.0–18.0 min)
whereas the total dWIT was 27.5 min (22.3–30.8 min).
The majority of the recipients was male, with a med-
ian age of 51.0 years (IQR, 46.0–56.5 years) in the
DCD‐reLT group and 56.0 years (IQR, 46.0–62.0 years)
in the DBD‐reLT group (P‐value = 0.22). The most
common indication for reLT was post‐transplant
cholangiopathy (43% in the DCD‐reLT group, 44% in
the DBD‐reLT group), followed by vascular complica-
tions and recurrence of the primary disease.
Table 2 shows operative data as well as data on the
postoperative outcomes.
Neither the CIT nor the rWIT differed significantly
between the two groups. However, the peak ALT level
in the first week post‐reLT was significantly higher in
the DCD‐reLT group (1346 IU/l vs. 833 IU/l, P‐
value = 0.04). Patients were discharged from the hospi-
tal after a median of 25 days in the DCD‐reLT group
and 20 days in the DBD‐reLT group (P‐value = 0.15).
Survival rates
The median follow‐up of the total cohort was 5.30 years
(IQR, 1.49–8.73 years). The 30 days, 1‐year, 5‐year, and
10‐year recipient survival in the DCD‐reLT group was
95%, 81%, 81%, and 81%, respectively, compared with
90%, 82%, 72%, and 59% in the DBD‐reLT group (P‐
value = 0.37, Fig. 1). The causes of death of five recipi-
ents in the DCD‐reLT group are listed in Table 3.
The 30 days, 1‐year, 5‐year, and 10‐year graft survival
was 95%, 81%, 81%, and 81% for the DCD‐reLT group
and 86%, 79%, 67%, and 53% in the DBD‐reLT group
(P‐value = 0.20) (Fig. 2). Six patients needed a subse-
quent retransplantation: three because of an early hep-
atic artery thrombosis (all in the DBD‐reLT group), two
due to ischemic‐type biliary lesions (one in each group),
and one patient in the DBD‐reLT group due to recur-
rence of primary sclerosing cholangitis.
Biliary complications
In total, 10.7% of the recipients had a bile leakage. Fur-
thermore, five recipients in the DCD‐reLT group
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(23.8%) and eight in the DBD‐reLT group (12.7%)
developed an anastomotic stricture (P‐value = 0.30).
The proportion of recipients developing NAS was sig-
nificantly higher in the DCD‐reLT group (38.1% vs.
12.7%, P‐value = 0.02). The majority of the NAS after
DCD‐reLT were of the focal type. The median time
interval between reLT and diagnosis of NAS was
170 days (IQR 102–282 days).
Table 1. Donor and recipient demographics.
Total group
N = 84
DCD‐reLT
N = 21
DBD‐reLT
N = 63 P‐value
Donor
Gender
Male 42 (50.0) 10 (47.6) 32 (50.8) 0.80
Female 42 (50.0) 11 (52.4) 31 (49.2)
Age (years) 40.5 (24.0–51.5) 38.0 (19.5–45.0) 42.0 (25.0–53.0) 0.11
BMI (kg/m2) 23.5 (21.3–26.0) 22.4 (19.8–23.7) 24.7 (21.5–26.7) 0.02
Cause of death
CVA 43 (51.2) 7 (33.3) 36 (57.1) 0.06
Trauma 26 (31.0) 7 (33.3) 19 (30.2)
Other 15 (17.9) 7 (33.3) 8 (12.7)
Last γ‐GT (U/L) 24 (17–52) 28 (18–34) 23 (17–53) 0.96
Last ALT (U/L) 32 (21–50) 23 (15–47) 36 (21–52) 0.10
Asystolic dWIT (min)* n/a 15.0 (12.0–18.0) n/a n/a
Total dWIT (min)† n/a 27.5 (22.3–30.8)‡ n/a n/a
Recipient
Gender
Male 54 (64.3) 12 (57.1) 42 (66.7) 0.43
Female 30 (35.7) 9 (42.9) 21 (33.3)
Age (years) 54.5 (46.0–61.8) 51.0 (46.0–56.5) 56.0 (46.0–62.0) 0.22
BMI (kg/m2) 24.3 (21.7–26.6) 22.7 (21.6–28.2) 24.3 (21.7–26.5) 0.77
Laboratory MELD score 20.0 (10.3–26.0) 19.0 (9.5–27.5) 20.0 (11.0–26.0) 0.70
Indication for reLT
PNF 7 (8.3) 3 (14.3) 4 (6.3) 0.41
Vascular (e.g., HAT/PVT) 23 (27.4) 3 (14.3) 20 (31.7)
Biliary (e.g., ITBL) 37 (44.0) 9 (42.9) 28 (44.4)
Recurrent primary disease 12 (14.3) 4 (19.0) 8 (12.7)
Other 5 (6.0) 2 (9.5) 3 (4.8)
High urgency status 26 (31.0) 4 (19.0) 22 (34.9) 0.17
Number of reLT
First reLT 72 (85.7) 18 (85.7) 54 (85.7) >0.99
Second reLT or more 12 (14.3) 3 (14.3) 9 (14.3)
Time between reLT and prior LT (days) 466 (13–2728) 1140 (166–3864) 368 (12–2685) 0.31
Graft type of prior LT
DBD graft 61 (72.6) 15 (71.4) 46 (73.0) 0.82
DCD graft 22 (26.2) 6 (28.6) 16 (25.4)
Living 1 (1.2) 0 1 (1.6)
Data are shown as median (IQR) and frequency (proportion).
P-values < 0.05 were considered statistically significant which are presented in bold.
ALT, alanine transaminase; BMI, Body Mass Index; CVA, cerebrovascular accident; DBD, donation after brain death; DCD,
donation after circulatory death; dWIT, donor Warm Ischemia Time; γ‐GT, Gamma‐glutamyltransferase; LT, liver transplanta-
tion; MELD, model for end‐stage liver disease; reLT, liver retransplantation.
*Asystolic dWIT is defined as the time between circulatory arrest and start of cold perfusion.
†
Total dWIT is defined as time between withdrawal of life‐supporting treatment and cold perfusion.
‡
Proportion of missing data for this variable is 23.8%.
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Discussion
The relative shortage of available liver grafts has led to a
more widespread use of DCD grafts. However, the out-
comes after reLT with a DCD graft have rarely been
reported in literature. This is the first study to analyze
the outcomes after DCD‐reLT and compare these with
outcomes after matched DBD‐reLT. Our results suggest
that reLT with a DCD graft in selected patients does
not result in inferior outcome when compared to
matched DBD‐reLTs.
The survival rates after DCD‐reLT in this study are
substantially higher than presented in the previous
study on DCD‐reLT performed by Perry et al. in 2011
(14). This could be due to the substantially lower
MELD score in our population (median of 20.0 vs. a
median of 27.0 reported by Perry et al.). Unfortunately,
it is unclear whether in the study by Perry et al. the
MELD score included (non) standard exception points.
Since our median laboratory MELD score is that much
lower, we are unable to refute or endorse the conclusion
from Perry et al. that the use of DCD grafts should be
avoided in high MELD recipients awaiting reLT. How-
ever, a recent published study by Taylor et al. concluded
that accepting a DCD graft has a survival advantage
over waiting for a DBD liver, especially in recipients
with a high MELD score (19). As this study only
included first‐transplant recipients, it is doubtful
whether the conclusions made by Taylor and colleagues
can be extrapolated to the field of reLT. Based on our
results, it is indicated that at least in recipients with
low‐to‐moderate laboratory MELD score the use of a
DCD graft is justifiable for reLT.
The significantly lower donor BMI in the DCD‐reLT
group is probably the result of strict selection by trans-
plant physicians and surgeons. Since there seems to be
some association between BMI and degree of steatosis, a
known risk factor for poor outcome after LT (20,21),
transplant professionals may be reluctant to accept the
liver from an overweight DCD donor for reLT. We
believe that it is unlikely that the lower donor BMI of
the DCD‐group alone has resulted in the relatively high
survival rates of this group, because median donor BMI
of both groups was within the healthy weight category
according to the WHO definition (22).
When compared with DBD grafts, LT with DCD
grafts is generally at higher risk of developing biliary
complications post‐transplantation, especially NAS. A
Table 2. Surgical and postoperative demographics.
Total group
N = 84
DCD‐reLT
N = 21
DBD‐reLT
N = 63 P‐value
Operation
rWIT (minutes) 40 (32.8–46.3) 44.0 (35.0–48.0) 39.0 (31.5–43.0)* 0.07
CIT (minutes) 444 (377–524) 440 (355–518) 448 (389–527) 0.69
Blood loss (ml)† 3600 (2000–5900) 4819 (2675–8175)† 3200 (1767–5450)‡ 0.09
Postoperative outcomes
ICU stay (days) 2.0 (1.3–5.0) 2.0 (2.0–4.0) 2.0 (1.0–5.0) 0.90
Hospital stay (days) 21.0 (14.0–30.0) 25.0 (14.0–34.5) 19.5 (13.0–25.8)§ 0.15
Peak ALT within 1st week 1011 (540–1626) 1346 (526–2518) 833 (526–1305) 0.04
Hepatic artery thrombosis 9 (10.7) 2 (9.5) 7 (11.1) >0.99
Bile leak 9 (10.7) 2 (9.5) 7 (11.1) >0.99
Anastomotic strictures 13 (15.5) 5 (23.8) 8 (12.7) 0.30
Nonanastomotic strictures 16 (19.0) 8 (38.1) 8 (12.7) 0.02
Death 24 (28.6) 5 (23.8) 19 (30.2) 0.58
Retransplantation 6 (7.1) 1 (4.8) 5 (7.9) >0.99
Data are shown as median (IQR) and frequency (proportion).
P-values < 0.05 were considered statistically significant which are presented in bold.
ALT, alanine transaminase; BAR, balance of risk; CIT, cold ischemia time; DBD, donation after brain death; DCD, donation after
circulatory death; ICU, Intensive Care Unit; LT, liver transplantation; MELD, model for end‐stage liver disease; reLT, liver retrans-
plantation; rWIT, recipient Warm Ischemia Time.
*Proportion of missing data for this variable is 3.2%.
†
Proportion of missing data for this variable is 4.8%.
‡
Proportion of missing data for this variable is 15.9%.
§
Proportion of missing data for this variable is 1.6%.
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similar trend can be seen in the current study. Although
the development of NAS post‐transplantation can have
a substantial influence on the survival rates, we believe
it should not discourage transplant professionals in
using DCD grafts for the indication of reLT. Firstly,
because the majority of the NAS cases reported after
DCD‐reLT in our study were of the focal type and
could be treated conservatively by endoscopic therapy.
Only two recipients required a new transplant because
of this complication. Furthermore, the field of machine
perfusion is evolving rapidly. Research has shown that
with the use of machine perfusion, the incidence of bil-
iary complications post‐transplant can be reduced (23–
26). Currently, several international trials regarding
machine perfusion are ongoing.
Surprisingly, the incidence of NAS after especially
DBD‐reLT in the current study is higher than
expected. There could be several explanations for this.
First, the high NAS incidence in the DBD‐cohort could
be the result of the matching. Furthermore, until
recently, the donor hepatectomy time (i.e., the time
between the start of cold perfusion in the donor and
the liver being stored on ice) was relatively long in the
Netherlands. Research has shown that a prolonged
hepatectomy time is a risk factor for the development
of NAS (27,28). Finally, the high incidences of NAS in
this reLT cohort could also imply that a reLT, inde-
pendent of graft type, has a higher risk of developing
postoperative NAS. Unfortunately, literature on this
topic is lacking.
With the renewed interest in the use of DCD grafts,
we believe that the results of our study are very relevant
for further practice in these centers. With careful selec-
tion, recipient and graft survival after DCD‐reLT appear
similar to the survival in DBD‐reLT. Therefore, grafts
for reLT should not be rejected based on the DCD sta-
tus alone but a careful assessment of additional donor
factors is needed for a case‐by‐case decision to use these
grafts. Furthermore, making use of DCD donors for
reLT may facilitate the current ethical debate regarding
reLT. That is, if transplant surgeons and physicians will
accept DCD grafts for retransplantation, more DBD
grafts will remain available for recipients on the waiting
list awaiting their first‐transplant. At the same time,
expansion of the donor pool with DCD donors will
result in more expedited reLT for those in need. Finally,
with the emerging technologies in the field of machine
perfusion, it can be anticipated that the quality of DCD
grafts can be improved, resulting in among other a
decreased incidence of post‐transplant cholangiopathy
(23,29,30).
One strength of this study is the comparison of out-
come after DCD‐reLT with a matched control group of
DBD‐reLT cases. This has made a proper comparison of
the two groups possible, from which it can be con-
cluded that survival after DCD‐reLT is under certain
circumstances similar to that after DBD‐reLT. This
study also has several limitations. Firstly, we had to
define dWIT as time between withdrawal of life support
and cold perfusion. We were unable to calculate the
Figure 1 Kaplan–Meier curve of patient survival after DCD‐reLT and
DBD‐reLT. Patient survival is defined as death (with or without func-
tioning graft). DBD‐reLT: liver retransplantation with graft from dona-
tion after brain death. DCD‐reLT: liver retransplantation with graft
from donation after circulatory death.
Table 3. Causes of death after DCD-reLT.
Patient Graft type
Interval
between
reLT and
death (days) Cause of death
1. DCD-reLT 1 Myocardial infarction
in septic patient
2. DCD-reLT 129 Multiple organ failure
3. DCD-reLT 129 Recurrent giant cell
hepatitis
4. DCD-reLT 205 Pseudomonas infection
in patient with
recurrent hepatitis
C infection
5. DCD-reLT 4941 Recurrent
decompensated liver
cirrhosis
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more important functional warm ischemia time in the
donor since data on hemodynamic status during the
agonal phase are lacking or improperly recorded. Fur-
thermore, the study had a retrospective design, which is
prone to bias and confounding. Finally, the sample size
of this study is relatively small, which made detailed sta-
tistical analysis such as multivariate analysis impossible.
In conclusion, reLT with a DCD graft can yield simi-
lar patient and graft survival rates as reLT with dona-
tion after brain death. Therefore, DCD itself should not
preclude the use of such donors in patients awaiting
retransplantation. However, careful selection of the
offered DCD livers probably remains mandatory, espe-
cially to minimalize the chance of developing NAS post‐
retransplantation. Larger studies are needed to confirm
our results.
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